Inovio Pharmaceuticals Inc. (INO) News

Inovio Pharmaceuticals Inc. (INO): $4.19

0.15 (+3.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

Filter INO News Items

INO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INO News Highlights

  • For INO, its 30 day story count is now at 5.
  • Over the past 13 days, the trend for INO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about INO are DNA, MRNA and RACE.

Latest INO News From Around the Web

Below are the latest news stories about Inovio Pharmaceuticals Inc that investors may wish to consider to help them evaluate INO as an investment opportunity.

Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | January 11, 2022

Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals

Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.

Yahoo | January 11, 2022

Is 15% Potential Upside Good Enough to Risk Buying Inovio Stock? Analyst Weighs In

immunotherapy programs for infectious diseases. Most of the focus so far, however, has been on the Covid-19 program for INO-4800.

Marty Shtrubel on TipRanks | December 30, 2021

Inovio assumed with Hold at Jefferies with $6 target

Jefferies analyst Roger Song assumed coverage of Inovio Pharmaceuticals (INO -2.4%) with a Hold rating and price target (PT) of $6, down from $8. The analyst believes near-term stock movement will likely be driven by the company's COVID-19 program and he's cautious on the Phase 3 efficacy results of experimental...

Seeking Alpha | December 29, 2021

Vontobel Holding Ltd. Buys 77,800 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Vontobel Holding Ltd. raised its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 69.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 189,556 shares of the biopharmaceutical company’s stock after acquiring an additional 77,800 shares during the period. Vontobel Holding Ltd.’s holdings in Inovio Pharmaceuticals were worth $1,357,000 as of its most recent […]

Dakota Financial News | December 23, 2021

Is Inovio Stock A Buy After The FDA Removed Its Hold On Covid Vaccine Testing?

Is INO stock a buy after the Food and Drug Administration removed a hold barring the Inovio from testing its Covid vaccine in the U.S.?

Yahoo | December 21, 2021

Inovio Pharmaceuticals (NASDAQ:INO) Is Using Debt Safely

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | December 19, 2021

Inovio Pharmaceuticals Inc. (NASDAQ: INO) Has Outstanding Potential

Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares, rose in value on Friday, 12/17/21, with the stock price up by 8.51% to the previous days close as strong demand from buyers drove the stock to $6.50. Actively observing the price movement in the last trading, the stock closed the session at $5.99, falling within a range of $5.90 Inovio Pharmaceuticals Inc. (NASDAQ: INO) Has Outstanding Potential Read More »

Stocks Register | December 18, 2021

A Sharp Uptick in Infections Reignites Fears of New Restrictions

NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local ...

Benzinga | December 17, 2021

Inovio: Making Progress in the Cervical HSIL Program

Inovio (INO) made a big splash last year with its Covid-19 DNA vaccine candidate INO-4800. Development, however, has been slow, and the vaccine is still a while away from entering the market, should it ever get that far. In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le

Yahoo | December 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5847 seconds.